EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma

Daniel M Geynisman, William S John, Taavy A Miller, Parisa Asgarisabet, Sarah B Guttenplan, Xin Yin, Kristin M Zimmerman Savill, Lindsay McAllister, Lisa Rosenblatt

The Oncologist · 2025

DOI: 10.1093/oncolo/oyae354 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Daniel M Geynisman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, United States. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Given the historical underrepresentation of racial minorities in clinical trials, little is known about racial differences in outcomes of first-line therapies for advanced renal cell carcinoma (aRCC). This study described patient characteristics and clinical outcomes of first-line therapies for aRCC, including nivolumab + ipilimumab, pembrolizumab + axitinib, and tyrosine kinase inhibitors, by race in the real-world setting.

Methods

We conducted a retrospective medical chart review of patients with intermediate/poor-risk clear-cell aRCC. Treating physicians abstracted patient data from electronic medical charts.

Results

Among 346 patients with intermediate/poor-risk aRCC, a higher proportion of African-American/Black (n = 78) versus White (n = 268) patients had poorer baseline functional performance (ECOG-PS ≥ 2: 37.2% versus 21.3%). African-American/Black patients trended toward numerically lower overall response rates and shorter overall survival for nivolumab + ipilimumab or pembrolizumab + axitinib than White patients.

Conclusions

These findings provide important insights into racial differences in first-line aRCC treatment outcomes within real-world settings. Additional research with larger sample sizes is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellKidney NeoplasmsAgedFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedBlack or African AmericanNivolumabRetrospective StudiesTreatment OutcomeWhite

Stichwörter der Autor:innen

ethnic and racial minoritiesnivolumabpembrolizumabrenal cell carcinomatyrosine kinase inhibitors

Substanzen

Antibodies, Monoclonal, HumanizedNivolumabpembrolizumab

Autor:innen und Institutionen

  • Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, United States.
  • Real-World Evidence and Insights, Cardinal Health, Dublin, OH 43017, United States.
  • Global Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ 08648, United States.

Zitieren

APA

Geynisman, D. M., John, W. S., Miller, T. A., Asgarisabet, P., Guttenplan, S. B., Yin, X., Savill, K. M. Z., McAllister, L., & Rosenblatt, L. (2025). Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyae354

Vancouver

Geynisman DM, John WS, Miller TA, Asgarisabet P, Guttenplan SB, Yin X, et al. Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma. The Oncologist. 2025. doi:10.1093/oncolo/oyae354

BibTeX
@article{Geynisman2025,
  author = {Geynisman, Daniel M and John, William S and Miller, Taavy A and Asgarisabet, Parisa and Guttenplan, Sarah B and Yin, Xin and Savill, Kristin M Zimmerman and McAllister, Lindsay and Rosenblatt, Lisa},
  title = {Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyae354}
}
Kostenlos starten →